A Phase 3 interventional study of Reproxalap Ophthalmic Solution (0.25%) and Vehicle Ophthalmic Solution in Dry Eye, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-18.
Sponsored by Aldeyra Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing reproxalap in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. reproxalap · Dry Eye Syndromes.
Among the 11 studies testing reproxalap in Dry Eye Syndromes, this one is the 3rd largest by enrollment, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 6th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →None of the 11 studies testing reproxalap in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 6
First in 2017; this study’s year is marked. 4 started in 2021.
This study's enrollment of 361 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 158 across the 11 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Aldeyra Therapeutics, Inc. is the lead sponsor of 35 studies on the registry; 1 is open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 25 (86%) have results posted.
13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 13 finished, 10 (77%) have results posted.
Among the 13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc., this one is the 4th largest by enrollment, is one of 4 that started in 2021, is one of 6 in phase 3, and was the 8th registered.
Aldeyra Therapeutics, Inc.’s Dry Eye Syndromes studies by the year they started, since 2017.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing reproxalap in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Aldeyra Therapeutics, Inc.’s 13 in Dry Eye Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The TRANQUILITY 2 Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Reproxalap Ophthalmic Solution (0.25%)
Drug: Vehicle Ophthalmic Solution
Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days
Vehicle Ophthalmic Solution administered 7 times over two consecutive days
Schirmer Test Mean Change From Baseline
Change from baseline comparison of reproxalap to vehicle for Schirmer test (0 to 35 mm). Higher scores represent greater tear production. The least squares mean (standard error) was derived from a mixed model repeated measures analysis of change from baseline, with baseline as a covariate, and time point and treatment group as factors.
Time frame: The efficacy assessment period was before and after the final dose on Day 1 (Dose 4). Baseline was approximately two weeks before dosing at Screening.
Number of Subject Eyes That Are Schirmer Test Responders
Comparison of reproxalap to vehicle for number of subject eyes that are Schirmer test responders (10 millimeters or more increase from baseline). A generalized estimating equation analysis was performed with baseline as a covariate, and time point and treatment group as factors.
Time frame: The efficacy assessment period was before and after the final dose on Day 1 (Dose 4). Baseline was approximately two weeks before dosing at Screening.
| Milestone | Reproxalap | Vehicle |
|---|---|---|
| Started | 181 | 180 |
| Completed | 168 | 168 |
| Not completed | 13 | 12 |
Change from baseline comparison of reproxalap to vehicle for Schirmer test (0 to 35 mm). Higher scores represent greater tear production. The least squares mean (standard error) was derived from a mixed model repeated measures analysis of change from baseline, with baseline as a covariate, and time point and treatment group as factors.
| length in millimeters | Reproxalap | Vehicle |
|---|---|---|
| Schirmer Test Mean Change From Baseline | 1.8 ± 0.4 | -0.5 ± 0.4 |
Comparison of reproxalap to vehicle for number of subject eyes that are Schirmer test responders (10 millimeters or more increase from baseline). A generalized estimating equation analysis was performed with baseline as a covariate, and time point and treatment group as factors.
| eyes | Reproxalap | Vehicle |
|---|---|---|
| Number of Subject Eyes That Are Schirmer Test Responders | 116 | 54 |
Collected over The safety assessment period was two days.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Reproxalap | 0/181 (0%) | 0/181 (0%) | 145/181 (80.1%) |
| Vehicle | 0/180 (0%) | 0/180 (0%) | 6/180 (3.3%) |
| Event | Reproxalap | Vehicle |
|---|---|---|
| General disorders and administration site conditionsGeneral disorders | 145/181 | 6/180 |
Intent-to-treat population
| Age, Categorical(Participants) | Reproxalap | Vehicle | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 83 | 98 | 181 |
| >=65 years | 98 | 82 | 180 |
| Age, Continuous(years) | Reproxalap | Vehicle | Total |
|---|---|---|---|
| Mean | 64.2 ± 12.2 | 61.9 ± 12.9 | 63.1 ± 12.6 |
| Sex: Female, Male(Participants) | Reproxalap | Vehicle | Total |
|---|---|---|---|
| Female | 123 | 126 | 249 |
| Male | 58 | 54 | 112 |
| Ethnicity (NIH/OMB)(Participants) | Reproxalap | Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 3 | 13 |
| Not Hispanic or Latino | 171 | 177 | 348 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Reproxalap | Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 9 | 10 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 25 | 36 | 61 |
| White | 147 | 132 | 279 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in Mar 2022, 6 months.
Results were first posted in Mar 2025, 3 years after primary completion. A results delay was requested in Feb 2023.
Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 6 months is below that.
Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Reproxalap